%0 Journal Article
%T Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis
%A Daisuke Suzuki
%A Hiroyuki Ohashi
%A Kaori Kobori
%A Kumiko Shimoyama
%A Masakatsu Hayakawa
%A Motohiro Suzuki
%A Noriyoshi Ogawa
%A Osamu Kimoto
%A Seiji Tsuboi
%A Shogo Furukawa
%A Taro Karahashi
%A Toshiaki Miyamoto
%A Yasuhiro Ota
%A Yoshinori Goto
%A Yuichiro Maekawa
%J Immunological Medicine
%D 2019
%R https://doi.org/10.1080/25785826.2019.1605036
%X Abstract The aim of this study was to assess abatacept in rheumatoid arthritis (RA) patient. Patients (20 men, 89 women, aged 61.9£¿¡À£¿10.4 y) who responded inadequately to conventional synthetic disease-modifying anti-rheumatic drug were treated with abatacept for 24-months. Disease activity score in 28 joints (DAS28-CRP) was evaluated. Of 109 patients, 82 (75.2%) were on methotrexate (MTX; mean dosage 9.0£¿¡À£¿2.7£¿mg/week); 48 (44.0%) were naive to biologics and 61 (56.0%) had failed biologics. The 1- and 2-year retention rates were 77% and 53%, respectively. At 24-months, the DAS28-CRP remission rates were 54.5% in the biologic-na£¿ve patients, and 28.2% in the biologic-failure patients (p£¿<£¿.01), while the structural remission rates were 83.9% and 73.1%, respectively (p£¿=£¿.461). Abatacept was equally effective in RA patients who were and were not on concomitant MTX. Biologic-na£¿ve was associated with better clinical outcome. Abatacept was effective in patients who showed decreasing anti-CCP antibody titers or serum MMP-3 levels during treatment. Infection was the most frequent adverse effect of abatacept therapy. In conclusion, abatacept is more effective in biologic-na£¿ve than in biologic-failure RA patients with or without concomitant use of MTX. Abatacept is more effective in RA patients with than without decreasing serum MMP-3 or anti-CCP antibody titers during treatment
%U https://www.tandfonline.com/doi/full/10.1080/25785826.2019.1605036